洛铂联合绿脓杆菌制剂治疗恶性胸腔积液的临床观察.pdf

正萌,等洛铂联合绿脓杆閑制剂治疗恶性胸液的临床观察
114] Takezawa K, Pirazzoli V, Arcila ME, et al. HER2 amplification: a
Between lights and shadows[J ] J Thorac Oncol, 2014, 12(9)
potential mechanism of acquired resistance to ECFR inhibition in
765-768.
ECFR 17 Takenaka M, Tlanagiri
1790M mutation IJ. Cancer Discov, 2012, 2(10): 922-933
cance of HER2 overexpression in non-small cell lung cancel
15 Takezawa K Melnick MA, Riely G Abstract A23: HER2 levels af
「J」. Anticancer Res,2011,31:4631-4636
fect sensitivity and resistance o EGFR inhibition in EGFR mutant 18 Tanizaki J Okamoto I, Okabe T, et al. Activation of TTFR family
lung cancer!J]. Clinical Cancer Research, 2012, 18(10suppl)
signaling as a mechanism of acquired resistance to ALK inhibitors
in EMTA-AT K-positive non-small cell lung cancer JI
16] Ricciardi GR, Russo A, Franchina T', ct al. NSCLC and HER2
Cancer Res,2012,18:6219-6226
(第校:闫沛)
洛铂联合绿胶杄菌制剂治疗恶性胸腔积液的临床观察
王萌,洪璇,杨朝阳,闫安,李晓莉
Clinical observation of Lobaplatin combined With PA-MSHA in the treatment of mlig
nant hydrothorax
Wang Meng, long Xuan, Yang Zhaoyang, Yan An, li Xiaoli
Departmen ofmedical Oncology, he id lated Hospital ofharbin Medical University, Heilon an Harbin 150081, Chi
Abstract Ob ective: To observe the clinical efficacy of lobaplatin combined with PA-MSHA in the treatment of
malignant hydrothorax. Methods: Lobaplatin combined with PA-MSHA was applied in 32 patients with malignant hy
drothorax(roup ) 30 patients with malignant hydrothorax treated by cisplatin and interleukin-2(roup B).Re
sults: Following a maxnium release of hydrothorax, among 32 cases(group A), 19 cases achieved CR, 11 cases SD, ob-
jective efficiency rate was 93.89. In the group 1, 10 cases achieved CR, 12 cases SD, objective efficiency rate was
73. 3, there was significant differences between two groups(P=0.029).Among 32 cases(group A), 29 cases of
atients were found to improve their quality of life(90.6%). Among 30 cases(group 13), 16 patients were found to
improve their quality of life(53. 3), here was si icant ifferences of two groups(P=0.001). Group A had a
significantly better response rate and QOL improvement rate than group B In two groups, the occurrence rates of grade
I II toxicities mainly including nausea, vomiting and fatigue, there was no significant differences(P>0.05). Conclu-
sion Lobaplatin combined with A- MSHA can control the malignant hydrothorax, clinical safety is better, it is wor
thy of clinical generalization
Key words]Lobaplatin, PA-MSHA, cisplatin, malignant hydrothorax
Modern Oncology 2016, 24(09): 1398-1400
摘要】目的:规察洛铂联合绿脓柑菌制剂治疗恶性胸腔积液的临床效果。方法:将62例恶性胸腔积液患者
引流排浄积液斤,32例忠者注入洛铂和绿脓杆菌制剂(A组);30例忠者注入顺铂和白介索-2(B组),观察
疗效、不良反应。结果:A组32例患者中,CR19例,SD11例,有效率为93.8%;B组30例忠者中,CR10例
SD12例,有效半73.3%,两者差异有统计学意义(P=0.029)。在A组32例忠者中,生活质量改善者29例
(90.6%);B组30例忠者中生活质量改苦者16例(53.3%),两者差异イ统计学意义(P=0.001)。A组有效
率和生:活质量改善率显著优于B组。炳组不良反成主要以1、Ⅱ度恶心、収吐,波乏为主,不良反炳组比较
差异均无统计学意义(P>0.05)。结论:洛钟联仚録脓村菌制剂治疗恶胸积液安全冇效,不良反应轻微
收稿日期】2015-05-04
【修阿H期】2015-07-06
【作者单位)哈尔浜医科人学附属肿翔医院呼吸内科,黑龙江.哈尔浜150081
作者简介】王萌(1979-),女,黑龙江哈尔滨人,副主任医师、博十,主要从事呼吸系统胂瘤的诊断和治疗工作。E-mal:_meng2002
alivun. com
通讯作者】李晓莉(1964-),女,黑龙江哈尔滨人,主任医师,博十,主要从事呼吸系统肿的诊断和治疗工作。